“…It was found that even when adequate and timely reperfusion therapy restored epicardial coronary blood flow, CMVD still occurred in many patients ( Niccoli et al, 2016 ). At present, the main therapeutic drugs used for CMVD are mainly anti-myocardial ischemia drugs, which include beta-blockers, short-acting nitrates, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), calcium channel blockers (CCB), ivabradine, trimetazidine, and ranolazine ( Task Force et al, 2013 ; Villano et al, 2013 ; Mumma and Flacke, 2015 ; Bairey Merz et al, 2016 ; Shah et al, 2017 ). Although these drugs have certain clinical efficacy, many patients still require repeated hospitalization and coronary angiography because of chest pain, which seriously affects patients’ quality of life ( Zhuang et al, 2020 ).…”